Literature DB >> 25773773

Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles.

Tomohiro Terada1, Daiki Hira.   

Abstract

The efficacy and safety of pharmacotherapies are determined by the complex processes involved in the interactions between drugs with the human body, including pharmacokinetic aspects. Among pharmacokinetic factors, it has been recognized that drug transporters play critical roles for absorption, distribution and excretion of drugs, regulating the membrane transport of drugs. The vast amounts of information on drug transporters collected in the past 20 years have been organized according to biochemical, molecular, genetic, and clinical analyses. Novel technologies, public databases, and regulatory guidelines have advanced the use of such information in drug development and clinical practice. In this review, we selected some clinically important drug transporters expressed in the intestine and liver, and introduced the research history and current knowledge of their pharmacokinetic, pathophysiological, and pharmacogenetic implications.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25773773     DOI: 10.1007/s00535-015-1061-4

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  81 in total

Review 1.  The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia.

Authors:  Dietrich Keppler
Journal:  Drug Metab Dispos       Date:  2014-01-23       Impact factor: 3.922

Review 2.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

Review 3.  Is there evidence to claim or deny association between variants of the multidrug resistance gene (MDR1 or ABCB1) and inflammatory bowel disease?

Authors:  Elias Zintzaras
Journal:  Inflamm Bowel Dis       Date:  2011-09-01       Impact factor: 5.325

Review 4.  The role and pathophysiological relevance of membrane transporter PepT1 in intestinal inflammation and inflammatory bowel disease.

Authors:  Sarah A Ingersoll; Saravanan Ayyadurai; Moiz A Charania; Hamed Laroui; Yutao Yan; Didier Merlin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-12-22       Impact factor: 4.052

Review 5.  Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy.

Authors:  Dietrich Keppler
Journal:  Handb Exp Pharmacol       Date:  2011

Review 6.  Role of ABCG2/BCRP in biology and medicine.

Authors:  P Krishnamurthy; J D Schuetz
Journal:  Annu Rev Pharmacol Toxicol       Date:  2006       Impact factor: 13.820

7.  ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin.

Authors:  B Tomlinson; M Hu; V W Y Lee; S S H Lui; T T W Chu; E W M Poon; G T C Ko; L Baum; L S Tam; E K Li
Journal:  Clin Pharmacol Ther       Date:  2010-02-03       Impact factor: 6.875

Review 8.  Emerging transporters of clinical importance: an update from the International Transporter Consortium.

Authors:  K M Hillgren; D Keppler; A A Zur; K M Giacomini; B Stieger; C E Cass; L Zhang
Journal:  Clin Pharmacol Ther       Date:  2013-04-08       Impact factor: 6.875

9.  Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.

Authors:  Masahide Fukudo; Yasuaki Ikemi; Yosuke Togashi; Katsuhiro Masago; Young Hak Kim; Tadashi Mio; Tomohiro Terada; Satoshi Teramukai; Michiaki Mishima; Ken-Ichi Inui; Toshiya Katsura
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

10.  The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma.

Authors:  Tomoyuki Mizuno; Masahide Fukudo; Tsuyoshi Fukuda; Tomohiro Terada; Min Dong; Tomomi Kamba; Toshinari Yamasaki; Osamu Ogawa; Toshiya Katsura; Ken-Ichi Inui; Alexander A Vinks; Kazuo Matsubara
Journal:  Ther Drug Monit       Date:  2014-06       Impact factor: 3.681

View more
  10 in total

1.  Association of Genetic Polymorphisms With Afatinib-induced Diarrhoea.

Authors:  Rintaro Sogawa; Chiho Nakashima; Tomomi Nakamura; Koji Takeuchi; Sakiko Kimura; Kazutoshi Komiya; Yutaka Narisawa; Shinya Kimura; Naoko Sueoka-Aragane
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Sex Differences in Intestinal P-Glycoprotein Expression in Wistar versus Sprague Dawley Rats.

Authors:  Christine M Madla; Yujia Qin; Francesca K H Gavins; Jing Liu; Liu Dou; Mine Orlu; Sudaxshina Murdan; Yang Mai; Abdul W Basit
Journal:  Pharmaceutics       Date:  2022-05-10       Impact factor: 6.525

3.  Effects of Gingko biloba extract on tissue distribution of fluoxetine and venlafaxine in rats.

Authors:  Saad Abdulrahman Hussain; Fatima Adnan Alzubaidi; Hayder Obayes Hashem
Journal:  J Intercult Ethnopharmacol       Date:  2015-06-30

4.  Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma.

Authors:  Yoshiaki Yamamoto; Ryouichi Tsunedomi; Yusuke Fujita; Toru Otori; Mitsuyoshi Ohba; Yoshihisa Kawai; Hiroshi Hirata; Hiroaki Matsumoto; Jun Haginaka; Shigeo Suzuki; Rajvir Dahiya; Yoshihiko Hamamoto; Kenji Matsuyama; Shoichi Hazama; Hiroaki Nagano; Hideyasu Matsuyama
Journal:  Oncotarget       Date:  2018-03-30

5.  Collagen vitrigel promotes hepatocytic differentiation of induced pluripotent stem cells into functional hepatocyte-like cells.

Authors:  Shun Nakai; Ima Shibata; Takahiro Shitamichi; Hiroyuki Yamaguchi; Nobuyuki Takagi; Tomoaki Inoue; Toshito Nakagawa; Jumpei Kiyokawa; Satoshi Wakabayashi; Tomoya Miyoshi; Eriko Higashi; Seiichi Ishida; Nobuaki Shiraki; Shoen Kume
Journal:  Biol Open       Date:  2019-07-02       Impact factor: 2.422

6.  CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation.

Authors:  Takuto Takahashi; Maryam A Mohamud; Angela R Smith; Pamala A Jacobson; Mutaz M Jaber; Abeer F Alharbi; James Fisher; Mark N Kirstein
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

7.  Factors Associated With Serum Estradiol Levels Among Postmenopausal Women Using Hormone Therapy.

Authors:  Intira Sriprasert; Naoko Kono; Roksana Karim; Howard N Hodis; Frank Z Stanczyk; Donna Shoupe; Wendy J Mack
Journal:  Obstet Gynecol       Date:  2020-10       Impact factor: 7.623

Review 8.  Interpretation of Drug Interaction Using Systemic and Local Tissue Exposure Changes.

Authors:  Young Hee Choi
Journal:  Pharmaceutics       Date:  2020-05-02       Impact factor: 6.321

Review 9.  Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment.

Authors:  Jose J G Marin; Rocio I R Macias; Maria J Monte; Elisa Herraez; Ana Peleteiro-Vigil; Beatriz Sanchez de Blas; Paula Sanchon-Sanchez; Alvaro G Temprano; Ricardo A Espinosa-Escudero; Elisa Lozano; Oscar Briz; Marta R Romero
Journal:  Cancers (Basel)       Date:  2020-09-11       Impact factor: 6.639

10.  Diurnal expression of MRP4 in bone marrow cells underlies the dosing-time dependent changes in the oxaliplatin-induced myelotoxicity.

Authors:  Mizuki Kato; Yuya Tsurudome; Takumi Kanemitsu; Sai Yasukochi; Yuki Kanado; Takashi Ogino; Naoya Matsunaga; Satoru Koyanagi; Shigehiro Ohdo
Journal:  Sci Rep       Date:  2020-08-10       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.